Ma ny expe rts believe that a polysomnograin to scree nfo r obstructive sleep apnea should be p erform ed on eve ry patient who has a history ofloud snoring and sleepiness. In contras t, the autho r believes that with a careful history and phys ical examination, there is no need to study all such patie nts, at least not until home po lyso mnog raphy units becom e as conve nient and economic al as pulse oximetry.
Introduction
Basing a diagnosis of obstructive sleep apnea (OSA) and its milder form, upper airway resistance syndrome (UARS), solely on a history of loud snoring is similar to diagnosing myoc ardial ischemi a solel y on a history of chest pain. Although there are some patient s who can be diagnosed with OSA or UARS on the basis of history alone, most patients present more of a diagnostic dilemma.
The history might be able to suggest the presenc e or abse nce of sleep disordered breath ing, but are its sensitivity and specificity adeq uate? Becaus e de finitive testingsuch as overn ight poly somnography (PSG) perform ed in a sleep laboratory or a hom e sleep evaluation-can be expensive and incon venient , there is a need for an accurate algorithm that would help the physician dia gno se or rule out OS A/UARS based on the history alone.
In one sense, the solution to the diagno stic dilemm a is easy : Simply perform a screening PSG on every patient who has a history of loud snoring and sleepiness . Many authors agree that this is the ideal approac h, but it requires no judgment and begs the question.' Obv iou sly, the physical exa mination, particularly the exami nation of the upper airway, adds much to makin g the diagnosis.
I have no perfect algor ithm , but I will co ver the points that I conside r to be the most important in maki ng the diagnosis of OS A/UARS by history alone. From Witn essed apneas. Apneas witness ed by the bed partner, particularly those of prolon ged dur ation (> 10 sec) , are one of the most important parts of the history. The numb er of these eve nts per night is also important , beca use the greater the number of event s, the more likely that significa nt OSA exis ts. The history from the bed partn er, if available, is important and should be sought.
Daytime som n olence. The end result of OSA is usually exc essiv e daytime somnolence. A detailed history can be obt ained fairly quic kly , particul arly when a standa rd form such as the Epworth sleepiness scale is used.' Thi s scale provides some quant itation of the likelihood of OSA or UARS . Th e problem is that many of us who do not have OSA are tired durin g the day as well, particul arly in the late afternoon. More significant is a history of falling asleep while driving or wor king with machinery, especially an episode that resulted in an accident or nearacci dent. A person who has experienced thi s type of eve nt has a more severe problem that stresses the need for a workup.
Obesity. Although fac tors concerning weight are usually co nsidere d as part of the physical examination, a history of we ight ga in and excessive weight (~2 0 % above the insurance tabl e for age and height ) sugges ts the presence of OSA . A large co llar size is also sugges tive.
Male gender. .OSA is more common in men than in wom en.
History of hypertension. Becau se hype rten sion is one of the sequelae of OSA , its presence ca n be helpful in mak ing the diagnosis.
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Treatment without testing
Several effectiv e office surgical procedures are avai lable to treat snoring, including laser-assisted uvulop alatopla sty (LAUP), uvulectomy, and radiofrequency palat e-ti ghtening procedure s. The elimination of snoring resolves a major sym ptom of obstructive sleep apnea, but at the same time it can give the patient and physi cian a false sense of security. The absence of snoring does not nece ssaril y mean the absence of slee p apnea; in fact , apnea only becom es more difficult to detect. The elim ination of daytime sleepiness and nighttime snoring suggests that a "cure" was achieved, but this might not be the case unless the cure is validat ed by testing. Is the relief of symptoms enough reason not to test? Wh at about other practitioners-dentists,~a mi ly phy sicians, etc.-who prescribe antisnoring devic es without conducting a sleep stud y? These types of circum stanc es support the argument that every patient should undergo a slee p study before any attempt is made to correct snoring.
I might be in the minority, but I believe that with a careful history and phy sical examination, there is no need to study every patient who snores. Howe ver, those patients who are not studied should be informed that they do have a risk of OSA or UARS . Furth erm ore, the surgeon should be aware that postoperati ve swelling after a snoring correction procedure such as aLAUP can temp ora rily worsen a preexisting sleep apnea conditi on.' Patients whom I might not screen are those who do not have any witnessed apneas, who do not have excessive daytime sleepiness or heart disease, who are not obese, and whose physical serious cardi ac event in a patient who has co ronary artery disease than in a patient whose heart is normal.
History of nasal obstruction or mouth breathing.
Loud snoring usuall y requires that the mouth be open dur ing sleep. Th is also might contribute to airway obstruction by the tongue base in the prone position .
Other factor s. There are four less important clues that might be helpful when glea ned from the histor y: I) a slow awakening from a general anesthetic, which suggests cent ral apnea; 2) a parent' s report of the presence of nightm ares and enures is in children or a histor y of narcolepsy or restless legs syndro me, any of which might lead to the diagnosis of other sleep disorders; 3) mornin g head ache , a nonspecifi c symptom that is regularly found in patients with OSA; and 4) a history of alcohol ingestion in the evening or the use of short-acting hypnotics or sedatives at bedtime, which can be contributing causes of OSA.
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ADVERSE REACTIONS
In Phase3clinical trial s, atotal of564 pati entswere treated withCIPRO ' HC DTIC. Adve rse events withatleast remoterel ati onshipto treatment included headache (1.2%) and pruritus (0.4%) . The following treatment-rel ated adverse events were each repo rted in a single pati ent: migraine, hypesthesia, paresthesia, fungal dermatitis, cough, rash, urtica ria, and alopecia. NDC 0065-8531-1 0 CIPRO' is a registered trademark of Bayer AG. At this time, I believe that we do not have an idea l screening test for sleep apnea that could be co nducted with simple equi pme nt, that wo uld allow a person to be teste d at home with minimal effort and cost, and that would be very like ly to rule out sleep apnea . In another article in this special series on sleep disor ders, which will appear in a subsequent issue of EAR, NOSE & THROAT JOURNAL, Davidson et al describe a home PSG unit tha t they fee l co uld provide j ust such a test , and more.' Time and experience will tell.
Cer tainly, one ca n screen for hypo xia as well as cer tain cardiac arrhyth mias at home with a record ing pulse oximeter, but oximetry tests for only part of the OSA problem. Is it enoug h? There is disagreement in the literature, but the general feeling is that oximetry is not adeq uate . I think it is better than no testing at all, as long as we understand what it is and is not meas uring . I believe the diag nosis of nocturnal hypoxia is an important part of scree ning . If our test cri teria are suc h that the sensitivity is high, say near 100% (i.e. , a low false-negative rate), and the specificity is lower (i.e., a higher false-pos itive rate), we sho uld be able to diag nose any significant OSA with hypoxia before we send the patien t for definitive preoperative test ing.
Series et al have desc ribed home oxi metry criteria that provide a sensitivity of 100% and a spec ific ity of 39 % for OSA co mpared with PSG.5When overnight oxygen saturation is abnorma l or when the patient has significant bradycardia or tachycardia, then more detailed testing sho uld be performed. Usi ng Series' criteria, a norma l home oximetry finding rules out hypoxia that produces OS A, but it does not rule out a sleep disorder that can co ntribute to fragmented sleep and dayt ime sleepine ss withou t hypoxia. Home PSG units will con tinue to become more user-friendl y, and I feel that whe n thei r ease of use and cost beg in to approach those of a recording pulse oximeter, then we all will be inclined to test eve ry patient we suspect of OSA.
Treatment for Negative Pressure and Otitis
Th e Otoven t me thod is des ig ned to t reat m any of th e complications associated wi t h negative ear pressu re caused by Eustach ian t ub e dys fu nctio n.
Otov ent can preve nt or tr eat Oti tis m edi a and can be an alternative to surgery.
Proven success in clin ical st udy. 
